zFree
Amarin Climbs on Vascepa Partnership for China
Insights - The private pharmaceutical company Eddingpharm will pay Amarin Corp (AMRN) $15 million for rights to develop and commercialize Amarin’s prescription-grade fish oil pill, Vascepa, in China, Hong … Continue Reading
Read Now
Investors Should be Paying Attention to Xencor
Insights - Xencor, Inc (XNCR) priced an equity financing on Wednesday morning, selling 7.5 million shares of common stock at $14.25 for gross proceeds of $106 million. … Continue Reading
Read Now
It’s only Monday and Biopharma Deals are already Dominating the Newsflow
Insights - Healthcare investors will be well-aware of Valeant's (VRX) $10 billion acquisition of Salix Pharmaceuticals (SLXP), announced over the weekend, but Monday morning has already been crammed full of biotech dealflow. Here's a quick recap.
Read Now
Our Weekly Healthcare Roundup
What Investors Should Know About Proposed (& Drastic) Changes to the FDA
Insights - A draft of the 21st Century Cures Act carries serious implications for biopharma. Longer exclusivity, a faster approval process, and even the chance to SELL some exclusivity for certain products.
Read Now
VBL and Celsus: An Unfortunate Double Whammy for Developmental Inflammatory Drugs
Insights - VBL Therapeutics (VBLT) and Celsus Therapeutics (CLTX) each announced disappointing Phase 2 results for their drug candidates in inflammatory indications.
Read Now